July 27th 2020
By Skylar Jeremias
A joint venture between Fujifilm Kyowa Kirin Biologics and AstraZeneca has received a positive biosimilar opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
By Tony Hagen
The Center for Biosimilars® (CfB) spoke with Adrian van den Hoven, director general of Medicines for Europe, and Diogo Piedade, market access manager for Medicines for Europe, about their scorecard report for biosimilar access in European markets.
July 24th 2020
For Biocon, overall revenues were up during the fiscal quarter that just ended, driven by strong revenues in its biosimilars and generics operations.
July 23rd 2020
As capacity at its 3 existing plants begins to run out, Samsung Biologics will add a fourth plant to its Incheon, Republic of Korea, site.
China-based Bio-Thera Solutions is breaking into the growing Russian biosimilar market by licensing the marketing rights for its unapproved golimumab biosimilar to Russian biopharmaceutical company Pharmapark.
July 22nd 2020
Biosimilar misinformation takes many forms, some of it institutionalized in the form of word usage and some of it deliberately disparaging, 2 executives of Sandoz and Boehringer Ingelheim contend.
July 21st 2020
In a webinar this week, experts discussed the business dynamics that prevent providers from being able to choose the lowest-cost biosimilars.
A recent article lays out some of the hurdles the biosimilars industry faces, from the perspectives of oncology providers.
July 20th 2020
As part of a project to build the first biosimilar factory in Malaysia, one of the initial products would be halal certified.
July 17th 2020
Celltrion Healthcare said an antiviral drug candidate is moving along in trials as a potential treatment for coronavirus 2019 (COVID-19).
